Lucid Diagnostics Inc. Stock Price, News & Analysis

Lucid Diagnostics Inc. (Nasdaq: LUCD) has expanded its reach by entering into agreements with three preferred provider organizations (PPOs) and a specialized laboratory network. These agreements provide in-network access to Lucid's EsoGuard® DNA test, aimed at early detection of esophageal precancer, to millions of covered lives. The company emphasizes its goal of securing broad commercial reimbursement for EsoGuard testing, which is crucial for its growth strategy. This innovative test addresses a significant healthcare need, with esophageal cancer having a high mortality rate.

Lucid Diagnostics Inc. (Nasdaq: LUCD), a cancer prevention medical diagnostics company, will host a business update conference call on August 15, 2022, at 4:30 PM EDT. CEO Lishan Aklog will present the company's near-term milestones and growth strategy, while CFO Dennis McGrath will discuss Q2 2022 financial results. The call can be accessed via phone or webcast on Lucid's investor relations page. Lucid focuses on early detection of esophageal precancer in GERD patients, leveraging its EsoGuard® test and EsoCheck® device.

PAVmed Inc. (NASDAQ: PAVM, PAVMZ) announced that its CEO, Dr. Lishan Aklog, was recognized as one of the Most Influential Black Executives in Corporate America for 2022 by Savoy. This acknowledgment highlights his leadership and contributions in the medical technology sector, including advancements in diagnostics and digital health. Dr. Aklog expressed gratitude for the honor and emphasized his commitment to leveraging technology for patient care.

Lucid Diagnostics, a cancer prevention diagnostics company, announces that Dr. Lishan Aklog will present at the CG 42nd Annual Growth Conference from August 8-11 at the InterContinental Boston. His presentation is scheduled for August 11 from 12:30 pm to 12:55 pm ET. Additionally, Dr. Aklog will participate in 1x1 investor meetings at the 7th Annual Needham Med Tech & Diagnostics 1x1 Conference on August 15-16. Lucid specializes in diagnostics for patients with GERD, using its EsoGuard and EsoCheck products for cancer prevention.

PAVmed Inc. (PAVM, PAVMZ) provided a business update and preliminary financial results for Q1 2022, reporting a GAAP net loss of approximately $16.9 million or $(0.20) per share. EsoGuard related revenues reached $0.2 million, with a significant 76% increase from Q4 2021. Operating expenses totaled $19.3 million, including $4.8 million in stock-based compensation. The company maintains a strong balance sheet with $64.7 million in cash. Notably, ACG has endorsed nonendoscopic biomarker screening, benefiting Lucid's EsoGuard DNA Test. A conference call is scheduled today at 4:30 PM EDT.

Lucid Diagnostics reported preliminary financial results for Q1 2022, revealing EsoGuard related revenues of $0.2 million and an operating loss of approximately $12.3 million, or $(0.35) per share. The company experienced a significant operational boost with a 76% increase in EsoGuard tests processed, totaling 533 tests. Lucid continues to expand its sales infrastructure and laboratory capabilities, having signed a payer agreement with MediNcrease Health Plans. However, operating expenses surged to $11.9 million, raising concerns over financial efficiency.

Lucid Diagnostics Inc. has signed its first commercial payer agreement with MediNcrease Health Plans, providing in-network access to its EsoGuard DNA test for over 8 million covered lives. This agreement allows patients at risk for esophageal cancer to receive early detection through EsoGuard, enhancing cancer prevention efforts. The partnership is seen as a strategic milestone, aiming to secure further agreements to expand coverage. This test is crucial as esophageal cancer is highly lethal, with a mortality rate exceeding 80% within five years of diagnosis.

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) will host a business update conference call on May 12, 2022, at 4:30 PM EDT. CEO Lishan Aklog will discuss the company's near-term milestones and growth strategy, while CFO Dennis McGrath will review the first quarter 2022 financial results. Participants can join by dialing provided numbers or via the company's investor relations website. PAVmed is a commercial-stage medical technology company with subsidiaries like Lucid Diagnostics, offering early detection tools for esophageal cancer and other innovative healthcare solutions.